Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics· ARPA-H PROSPR Program
Melior Discovery will conduct preclinical in vivo pharmacology studies supporting Linnaeus' ARPA-H PROSPR-funded development of LNS880l for healthspan preservation EXTON, Pa., July 21, 2026 /PRNewswire-PRWeb/ -- Melior Discovery, Inc. (Melior), a dedicated in vivo pharmacology contract research organization (CRO) with deep expertise in phenotypic screening and preclinical model development, today…
Read More

